AHA ACS CKD pharmacotherapy statement 2015

AHA Scientific Statement Pharmacotherapy in Chronic Kidney Disease Patients Presenting With Acute Coronary Syndrome A Scientific Statement From the American Heart Association Jeffrey B Washam, PharmD, FAHA, Chair; Charles A Herzog, MD, FAHA; Amber L Beitelshees, PharmD, MPH, FAHA; Mauricio G Cohen, MD; Timothy D Henry, MD; Navin K Kapur, MD; Jessica L Mega, MD, MPH, FAHA; Venu Menon, MD, FAHA; Robert L Page II, PharmD, MSPH, FAHA; L Kristin Newby, MD, MHS, FAHA, Co-Chair; on behalf of the American Heart Association Clinical Pharmacology Committee of the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, Council on Functional Genomics and Translational Biology, Council on the Kidney in Cardiovascular Disease, and Council on Quality of Care and Outcomes Research C Background and CKD Staging hronic kidney disease (CKD) is frequently encountered among patients presenting with acute coronary syndrome (ACS) Recent data from the National Cardiovascular Data Registry–Acute Coronary Treatment and Intervention Outcomes Network (NCDR-ACTION) reported CKD (defined as estimated creatinine clearance [CrCl]